AbbVie Inc (ABBV)vsZEN Graphene Solutions Ltd (ZTEK)
ABBV
AbbVie Inc
$294.48
-0.18%
HEALTHCARE · Cap: $521.11B
ZTEK
ZEN Graphene Solutions Ltd
$0.49
0.00%
HEALTHCARE · Cap: $62.30M
Smart Verdict
WallStSmart Research — data-driven comparison
AbbVie Inc generates 60982809% more annual revenue ($66.01B vs $108,250). ABBV leads profitability with a 15.7% profit margin vs 0.0%. ABBV earns a higher WallStSmart Score of 77/100 (B+).
ABBV
Strong Buy77
out of 100
Grade: B+
ZTEK
Avoid15
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-85.2%
Fair Value
$157.29
Current Price
$294.48
$137.19 premium
Margin of Safety
-21.2%
Fair Value
$0.54
Current Price
$0.49
$0.05 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 62 in profit
Strong operational efficiency at 37.2%
Earnings expanding 2282.0% YoY
Conservative balance sheet, low leverage
Growing faster than its price suggests
Conservative balance sheet, low leverage
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ABBV
The strongest argument for ABBV centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 15.7% and operating margin at 37.2%. Revenue growth of 10.3% demonstrates continued momentum.
Bull Case : ZTEK
The strongest argument for ZTEK centers on Debt/Equity.
Bear Case : ABBV
The primary concerns for ABBV are P/E Ratio, Altman Z-Score. A P/E of 50.7x leaves little room for execution misses.
Bear Case : ZTEK
The primary concerns for ZTEK are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
ABBV profiles as a mature stock while ZTEK is a value play — different risk/reward profiles.
ZTEK carries more volatility with a beta of 0.29 — expect wider price swings.
ABBV is growing revenue faster at 10.3% — sustainability is the question.
ABBV generates stronger free cash flow (7.3B), providing more financial flexibility.
Bottom Line
ABBV scores higher overall (77/100 vs 15/100), backed by strong 15.7% margins and 10.3% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AbbVie Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories.
ZEN Graphene Solutions Ltd
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
ZEN Graphene Solutions Ltd (ZTEK) is an innovative leader in the materials technology sector, specializing in the extraction and commercialization of high-purity graphene derived from natural graphite. Through its proprietary techniques, ZTEK is poised to impact numerous industries, including energy storage, environmental remediation, and advanced manufacturing, offering cutting-edge graphene solutions. The company’s strategic focus on sustainability, underpinned by significant research and development initiatives, enhances its competitive edge in the rapidly expanding graphene market. As ZTEK leverages emerging opportunities and continues to advance its technological capabilities, it is well-positioned to deliver substantial long-term value for investors in the context of rising global demand for innovative and advanced materials.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?